What is QuanDx?
QuanDx operates at the intersection of clinical diagnostics and personalized medicine, specializing in the development of high-precision molecular tests. By leveraging proprietary technologies such as Q-Fusion and Yin-Yang Probes, the company provides rapid, cost-effective solutions for detecting leukemia, breast cancer, lung cancer, and colorectal cancer, as well as high-risk HPV. Their market position is defined by a commitment to improving diagnostic accuracy, which is essential for tailoring cancer treatments to individual patient profiles. Through its focus on scalable diagnostic infrastructure, QuanDx serves as a vital link in the modern healthcare value chain, enabling clinicians to make data-informed decisions that directly impact patient outcomes.
The company's growth history reflects a disciplined approach to scaling, beginning with its initial Series A round in 2013, followed by a significant Series B injection in 2015, and culminating in recent debt financing to support ongoing commercialization efforts.
How much funding has QuanDx raised?
QuanDx has raised a total of $3.3M across 3 funding rounds:
Series A
$300K
Series B
$3M
Debt
$23K
Series A (2013): $300K, investors not publicly disclosed
Series B (2015): $3M, investors not publicly disclosed
Debt (2021): $23K supported by PPP
Key Investors in QuanDx
PPP
Public-Private Partnership
Undisclosed Investor
A strategic partner involved in the early-stage capitalization of the firm's molecular diagnostic technology.
Undisclosed Investor
A venture-focused entity that provided significant growth capital during the company's Series B expansion phase.
What's next for QuanDx?
With the recent influx of capital, QuanDx is well-positioned to accelerate the commercial deployment of its diagnostic suite. The strategic focus will likely shift toward expanding market penetration for its existing oncology portfolio and potentially scaling its manufacturing capabilities to meet rising clinical demand. As the healthcare industry continues to prioritize early detection and personalized therapeutic interventions, QuanDx's ability to integrate its proprietary probes into standard clinical workflows will be a key determinant of its long-term success. Future milestones will likely involve deepening partnerships with clinical laboratories and expanding the regulatory footprint of its diagnostic assays to reach broader international markets.
See full QuanDx company page
